Building foundations for the future: The First European bank for iPS

Ever since the discovery of induced pluripotent stem cells (iPS) by Shinya Yamanaka in 2006 there has been much optimism of it's potential for therapy, overcoming the ethical dilemmas surrounding embryonic stem cells. They also allow for study of disease specific by generation of iPS from subject with a genetic disease


The EA consortium of 26 different stakeholders from big pharma, SMEs and academic groups are behind the first European bank of iPS. This will allow for robust generation of quality, customised cell lines that can meet future demand, to quality criteria, with a suitable distribution network. Although iPS products are still along way of market authorisation, there are still many researchers requiring access to iPS lines. A European wide bank gives access to improving research while laying a vital foundation for future therapies.
The EiSC will look to be operational within 3 years and operate as a not-for-profit bank. This will put the UK as a major focal point as iPS research within Europe.

The main facility will be at Babraham Research Campus in Cambridge, coordinated by Neusentis (Pfizer), and managed by Rosilin Cells.
The groups, from 9 different countries, partnered with the project include:


EFPIA companies
  • Neusentis, a Research Unit of Pfizer Ltd, UK
  • Novo Nordisk, Denmark
  • AstraZeneca AB, Sweden
  • H. Lundbeck A/S, Denmark 
  • Janssen Pharmaceutica NV, a Pharmaceutical Company of Johnson & Johnson, Belgium
  • UCB Pharma SA, Belgium
 SME’s
  • Roslin Cells Ltd, UK
  • ARTTIC, France
  • DefiniGEN Ltd, UK
  • Douglas Connect GmbH, Switzerland
  • Bioneer A/S, Denmark
  • European ScreeningPort, Germany 
 Universities, research organisations, public bodies, non-profit groups
  • University of Edinburgh, UK
  • Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (Fraunhofer-Institut für Biomedizinische Technik), Germany 
  • Genome Research Limited (Wellcome Trust Sanger Institute), UK
  • European Molecular Biology Laboratory (European Bioinformatics Institute), UK
  • Charité University Medicine Berlin, Germany
  • University of Newcastle Upon Tyne, UK
  • Klinikum Der Universitaet Zu Koeln, Germany
  • Gottfried Wilhelm Leibniz Universitaet Hannover, Germany
  • Koninklijke Nederlandse Academie van Wetenschappen (The Hubrecht Institute), The Netherlands
  • University College London, UK
  • Universitaetsklinikum Bonn, Germany
  • Culture Collections of PHE, UK
  • National Institute for Biological Standards and Control, UK
  • Instituto de Salud Carlos III. (Spanish Stem Cell Bank), Spain
For more information and updates go to the EBiSC website

No comments:

Post a Comment